Han Ying - Aug 14, 2024 Form 4 Insider Report for GYRE THERAPEUTICS, INC. (GYRE)

Role
Chief Executive Officer, Director
Signature
/s/ Ruoyu Chen, as attorney-in-fact for Han Ying
Stock symbol
GYRE
Transactions as of
Aug 14, 2024
Transactions value $
$0
Form type
4
Date filed
8/16/2024, 08:50 PM
Previous filing
Nov 1, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GYRE Stock Option (Right to Buy) Award $0 +341K $0.00 341K Aug 14, 2024 Common Stock 341K $9.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase a total of 341,000 shares of the Issuer's common stock, 25% of which will vest on August 14, 2025, with the remaining vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.